Skip navigation
Skip navigation

Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab

Gillies, Mark C; Campain, Anna; Walton, Richard; Simpson, Judy M; Arnold, Jennifer J; Guymer, Robyn H; McAllister, Ian L; Hunyor, Alex P; Essex, Rohan; Morlet, Nigel; Barthelmes, Daniel


PURPOSE: To characterize in more detail routine treatment patterns of intravitreal ranibizumab for neovascular age-related macular degeneration (nAMD), we analyzed the length of time and the number of injections required until lesions with choroidal neovascularization (CNV) were first graded inactive. DESIGN: Database observational study. PARTICIPANTS: Treatment-naïve eyes receiving predominantly ranibizumab for nAMD in routine clinical practice that were tracked in the Fight Retinal Blindness!...[Show more]

CollectionsANU Research Publications
Date published: 2015-03
Type: Journal article
Source: Ophthalmology
DOI: 10.1016/j.ophtha.2014.10.001


There are no files associated with this item.

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator